BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 1391947)

  • 1. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.
    Nash RA; Pepe MS; Storb R; Longton G; Pettinger M; Anasetti C; Appelbaum FR; Bowden RA; Deeg HJ; Doney K
    Blood; 1992 Oct; 80(7):1838-45. PubMed ID: 1391947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
    Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
    Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute graft-versus-host disease prophylaxis with methotrexate and cyclosporine after busulfan and cyclophosphamide in patients with hematologic malignancies.
    von Bueltzingsloewen A; Belanger R; Perreault C; Bonny Y; Roy DC; Lalonde Y; Boileau J; Kassis J; Lavallee R; Lacombe M
    Blood; 1993 Feb; 81(3):849-55. PubMed ID: 8427977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group.
    Morishima Y; Morishita Y; Tanimoto M; Ohno R; Saito H; Horibe K; Hamajima N; Naito K; Yamada K; Yokomaku S
    Blood; 1989 Nov; 74(6):2252-6. PubMed ID: 2804362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
    Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients.
    Kohno A; Morishita Y; Iida H; Sakamaki H; Yokozawa T; Kitaori K; Ozeki K; Matsuo K; Sao H
    Int J Hematol; 2006 Jul; 84(1):83-9. PubMed ID: 16867909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
    Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
    Radich JP; Sanders JE; Buckner CD; Martin PJ; Petersen FB; Bensinger W; McDonald GB; Mori M; Schoch G; Hansen JA
    J Clin Oncol; 1993 Feb; 11(2):304-13. PubMed ID: 8426208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
    Mielcarek M; Martin PJ; Leisenring W; Flowers ME; Maloney DG; Sandmaier BM; Maris MB; Storb R
    Blood; 2003 Jul; 102(2):756-62. PubMed ID: 12663454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
    Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
    Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marrow transplant experience for children with severe aplastic anemia.
    Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia.
    Weaver CH; Clift RA; Deeg HJ; Storb R; Appelbaum FR; Bensinger W; Doney K; Hansen JA; Martin PO; Sanders J
    Bone Marrow Transplant; 1994 Dec; 14(6):885-93. PubMed ID: 7711667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
    Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
    Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants.
    Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringdén O
    Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine.
    Irle C; Deeg HJ; Buckner CD; Kennedy M; Clift R; Storb R; Appelbaum FR; Beatty P; Bensinger W; Doney K
    Leuk Res; 1985; 9(10):1255-61. PubMed ID: 3906282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
    Wagner JL; Seidel K; Boeckh M; Storb R
    Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
    Storb R; Pepe M; Anasetti C; Appelbaum FR; Beatty P; Doney K; Martin P; Stewart P; Sullivan KM; Witherspoon R
    Blood; 1990 Sep; 76(5):1037-45. PubMed ID: 2203481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.